Literature DB >> 14991825

Pael-R is accumulated in Lewy bodies of Parkinson's disease.

Tetsuro Murakami1, Mikio Shoji, Yuzuru Imai, Haruhisa Inoue, Takeshi Kawarabayashi, Etsuro Matsubara, Yasuo Harigaya, Atsushi Sasaki, Ryosuke Takahashi, Koji Abe.   

Abstract

We examined the distribution of Pael-R, a newly identified substrate for Parkin, in Parkinson's disease (PD) and multiple system atrophy (MSA). Pael-R, Parkin, alpha-synuclein, and ubiquitin accumulated in Lewy bodies (LBs) and neurites. Pael-R was localized in the core of LBs. Parkin and alpha-synuclein accumulated in the halo, neuronal cell bodies, and processes. These findings potentially suggest the involvement of Pael-R in LB formation, and protection role of Parkin in Pael-R-mediated neurotoxicity in PD. The absence of Pael-R and Parkin in glial cytoplasmic inclusions (GCIs) in MSA implies a distinct pathway involved in the formation of LBs and GCIs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14991825     DOI: 10.1002/ana.20064

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  45 in total

Review 1.  The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

Authors:  Christopher J Guerriero; Jeffrey L Brodsky
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 2.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

Review 3.  Aggresome formation and neurodegenerative diseases: therapeutic implications.

Authors:  J A Olzmann; L Li; L S Chin
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

4.  Distinct mechanisms of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine resistance revealed by transcriptome mapping in mouse striatum.

Authors:  R Pattarini; Y Rong; C Qu; J I Morgan
Journal:  Neuroscience       Date:  2008-07-08       Impact factor: 3.590

Review 5.  Neuroproteomics as a promising tool in Parkinson's disease research.

Authors:  Ilse S Pienaar; William M U Daniels; Jürgen Götz
Journal:  J Neural Transm (Vienna)       Date:  2008-06-04       Impact factor: 3.575

6.  GPR37L1 modulates seizure susceptibility: Evidence from mouse studies and analyses of a human GPR37L1 variant.

Authors:  Michelle M Giddens; Jennifer C Wong; Jason P Schroeder; Emily G Farrow; Brilee M Smith; Sharon Owino; Sarah E Soden; Rebecca C Meyer; Carol Saunders; J B LePichon; David Weinshenker; Andrew Escayg; Randy A Hall
Journal:  Neurobiol Dis       Date:  2017-07-06       Impact factor: 5.996

7.  Mice lacking Gpr37 exhibit decreased expression of the myelin-associated glycoprotein MAG and increased susceptibility to demyelination.

Authors:  Brilee M Smith; Michelle M Giddens; Jessica Neil; Sharon Owino; TrangKimberly T Nguyen; Duc Duong; Fengqiao Li; Randy A Hall
Journal:  Neuroscience       Date:  2017-06-20       Impact factor: 3.590

8.  Accelerating the reversal of inflammatory pain with NPD1 and its receptor GPR37.

Authors:  Lintao Qu; Michael J Caterina
Journal:  J Clin Invest       Date:  2018-07-16       Impact factor: 14.808

9.  PINK1, a gene product of PARK6, accumulates in alpha-synucleinopathy brains.

Authors:  Tetsuro Murakami; Yasuhiro Moriwaki; Takeshi Kawarabayashi; Makiko Nagai; Yasuyuki Ohta; Kentaro Deguchi; Tomoko Kurata; Nobutoshi Morimoto; Yasushi Takehisa; Etsuro Matsubara; Masaki Ikeda; Yasuo Harigaya; Mikio Shoji; Ryosuke Takahashi; Koji Abe
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-01-08       Impact factor: 10.154

10.  Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease.

Authors:  Tomás González-Hernández; Ignacio Cruz-Muros; Domingo Afonso-Oramas; Josmar Salas-Hernandez; Javier Castro-Hernandez
Journal:  Front Neuroanat       Date:  2010-10-20       Impact factor: 3.856

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.